PACTG 382: DMP 266 & NELFINAVIR COMBINATION IN HIV-INFECTED CHILDREN (AIDS)

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。这是一项开放标签、AUC 对照研究，旨在确定液体依非韦伦与奈非那韦联合治疗 HIV 感染婴儿和儿童的给药方案、安全性和药代动力学。次要目标是表征该组合对 PBMC 中潜伏病毒的抗病毒活性、CD4/CD8 计数、反应持续时间和基因型/表型抗逆转录病毒敏感性的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open label, AUC controlled study to determine the dosing regimen, safety and pharmacokinetics of liquid efavirenz in combination with nelfinavir in HIV-infected infants and children. Secondary objectives are to characterize the effect of this combination on antiviral activity, CD4/CD8 counts, duration of response and genotypic/phenotypic antiretroviral sensitivity of latent virus in PBMCs.